Írország -
angol -
HPRA (Health Products Regulatory Authority)
xatral 10 milligram tablet prolonged release
clear pharmacy - alfuzosin hydrochloride - tablet prolonged release - 10 milligram
Írország -
angol -
HPRA (Health Products Regulatory Authority)
zoton fastab 15 milligram orodispersible tablet
clear pharmacy - lansoprazole - orodispersible tablet - 15 milligram - proton pump inhibitors
Írország -
angol -
HPRA (Health Products Regulatory Authority)
zoton fastab 30 milligram orodispersible tablet
clear pharmacy - lansoprazole - orodispersible tablet - 30 milligram - proton pump inhibitors
Szingapúr -
angol -
HSA (Health Sciences Authority)
peg-intron for injection 100 mcg/0.5 ml
msd pharma (singapore) pte. ltd. - peginterferon alfa-2b - injection, powder, for solution - 100 mcg/0.5 ml
Szingapúr -
angol -
HSA (Health Sciences Authority)
peg-intron for injection 120 mcg/0.5 ml
msd pharma (singapore) pte. ltd. - peginterferon alfa-2b - injection, powder, for solution - 120 mcg/0.5 ml
Szingapúr -
angol -
HSA (Health Sciences Authority)
peg-intron for injection 150 mcg/0.5 ml
msd pharma (singapore) pte. ltd. - peginterferon alfa-2b - injection, powder, for solution - 150 mcg/0.5 ml
Szingapúr -
angol -
HSA (Health Sciences Authority)
peg-intron for injection 50 mcg/0.5 ml
msd pharma (singapore) pte. ltd. - peginterferon alfa-2b - injection, powder, for solution - 50 mcg/0.5 ml
Szingapúr -
angol -
HSA (Health Sciences Authority)
peg-intron for injection 80 mcg/0.5 ml
msd pharma (singapore) pte. ltd. - peginterferon alfa-2b - injection, powder, for solution - 80 mcg/0.5 ml
Egyesült Királyság -
angol -
myHealthbox
ziclaseg 30mg prolonged-release tablets
lupin (europe) limited - gliclazide - prolonged-release tablet - 30mg - sulfonamides, urea derivatives - non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.
Egyesült Királyság -
angol -
myHealthbox
ropilynz xl 2 mg prolonged-release tablets
lupin (europe) limited - ropinirole - prolonged-release tablet - 2 mg - dopamine agonists - treatment of parkinson's disease under the following conditions: initial treatment as monotherapy, in order to delay the introduction of levodopa in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations).